Counterfeit and Overdiluted Products

A supplier offers a clinician in Madison, New Jersey a product that looks right but whose origin cannot be confirmed. The clinician is trained and careful. That is the complication, and the published guidance below leaves it open. The U.S. Food and Drug Administration has a page titled FDA-Approved Dermal Fillers.

Two routes and two results

An article hosted by PubMed Central states: "Some untrained providers might purchase counterfeit products or overdilute products resulting in increased risk of infection or reduced efficacy." It names two routes, buying counterfeit product and overdiluting product. It names two results, a higher risk of infection and reduced efficacy.

What the clinician's situation adds

The passage speaks of untrained providers. It does not say what a trained clinician should do when offered a product of unclear origin. The situation adds a decision at the point of purchase, before anything reaches a patient. The U.S. Food and Drug Administration also publishes an overview of dermal fillers under the title Dermal Fillers (Soft Tissue Fillers).

What stays open

The passage does not say how to spot a counterfeit or overdiluted product. It does not say how common either one is. It does not say how any New Jersey rule treats them. Those gaps stay open here.

Treat the product's source as patient risk

The passage supports one cautious step. Treat the source of a product as part of patient risk, since the passage ties counterfeit and overdiluted product to infection risk and reduced efficacy. For fillers specifically, the agency's dermal filler do's and don'ts is a further read.